Ganirelix vs Triptorelin
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Ganirelix
250–250 mcg
Triptorelin
11.25–11.25 mg
Frequency
Ganirelix
Once daily
Triptorelin
Once daily
Administration
Ganirelix
Subcutaneous injection
Triptorelin
Intramuscular injection
Cycle length
Ganirelix
Ongoing/indefinite
Triptorelin
Ongoing/indefinite
Onset speed
Ganirelix
Moderate (1-2 weeks)
Triptorelin
Moderate (1-2 weeks)
Evidence level
Ganirelix
Strong human trials (Phase 3 or FDA approved)
Triptorelin
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Ovulation Control
IVF Success Improvement
Safety & OHSS Prevention
Hormone Regulation
Cancer Management
Endometriosis Relief
Compound specifications
Ganirelix
Molecular formula
C80H113ClN18O13
Molecular weight
1570.4 g/mol
Half-life
10-12 hours
Bioavailability
~91% (subcutaneous injection)
CAS number
124904-93-4
Triptorelin
Molecular formula
C64H82N18O13
Molecular weight
1311.4 g/mol
Half-life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS number
57773-63-4
Dosing compared
Ganirelix
Subcutaneous
250 mcg
Once daily during the mid-to-late follicular phase · Continued daily until the day of hCG administration (typically about 5-9 days)
FDA-labeled dose for inhibiting premature LH surges during controlled ovarian stimulation; started after several days of FSH and continued until hCG trigger [4].
Triptorelin
Intramuscular injection
3.75 mg
Once every 4 weeks · Ongoing while indicated
FDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
11.25 mg
Once every 12 weeks · Ongoing while indicated
FDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
22.5 mg
Once every 24 weeks · Ongoing while indicated
FDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].
Best suited for
Ganirelix
Improving IVF or ICSI success rates
Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature ovulation during egg retrieval cycles
Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Controlling ovarian stimulation in women with unpredictable cycles
Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Triptorelin
Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Ganirelix
Common
- Mild discomfort at treatment site
- Injection site reactions (redness, bruising, swelling)
- Headaches
- Abdominal pain
- Pelvic discomfort
- Nausea
- Fatigue or dizziness
Serious
- Severe allergic reaction
Triptorelin
Safety & evidence
Ganirelix
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Ganirelix carries an excellent safety record from over 10,000 patients in FDA approval trials and 25+ years of clinical fertility practice. The antagonist mechanism avoids the flare effect seen with GnRH agonists, making it safer for women with diminished ovarian reserve. Injection site reactions are the most common issue (20-40% of patients), though typically mild bruising rather than systemic toxicity. The rapid 1-2 hour onset and quick clearance mean side effects resolve quickly if dosing is adjusted.
Contraindications
- Pregnancy or suspected pregnancy
- Breastfeeding
- Known allergies to any medication component
- Ovarian cysts larger than 3cm
Triptorelin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.
Contraindications
- Pregnancy (can affect fetal development)
- Undiagnosed vaginal bleeding
- Known hypersensitivity to GnRH agonists
- Severe untreated depression
- Active spinal cord compression in prostate cancer (requires urgent decompression)
Which is right for you?
Choose Ganirelix if...
- Improving IVF or ICSI success rates
- Preventing premature ovulation during egg retrieval cycles
- Controlling ovarian stimulation in women with unpredictable cycles
Choose Triptorelin if...
- Managing advanced prostate cancer when combined with other treatments
- Relieving severe endometriosis pain and symptoms
- Delaying puberty development in children with early sexual maturation